PSA Test: Normal Range by Age, High PSA and Cost in India

Written by TSMC/FMR/36195 · Published: October 20th, 2026 · 25 min read · 53 references
A Sapiens-branded blood collection tube labelled PSA, with a ribbed cream cap and dark red blood inside, lying diagonally on a soft peach surface in warm sunlight and casting a long shadow. Text on the left reads: Prostate health. PSA, explained.

Most men have a PSA below 4 ng/mL, the level India's urology guideline suggests as the point for further tests.1 PSA is prostate-specific antigen, a protein your prostate makes. PSA tends to rise with age. In 86,728 healthy Indian men, 95 in 100 were at or under 1.7 ng/mL at 41 to 50, 3.1 at 51 to 60 and 5.8 at 61 to 70.2

Those age figures show where 95 in 100 men at Indian health checkups fell. They are not cancer cut-offs or official Indian ranges, and India's urology guideline has no age chart of its own.2, 1 A result above the usual range for your age may call for a repeat test and a review with your doctor, and age is only one part of that decision. On a second test, a newly raised PSA comes back normal in 25 to 40 of every 100 men.3 A biopsy is a sample of prostate tissue taken with a needle. Among men who have one because of a raised PSA, about 25 in 100 have cancer, according to the US National Cancer Institute.4 MRI scans now help choose who needs a biopsy, which changes that mix.5 And a tablet some men take for hair loss pushes the number down. At 1 mg a day, the hair-loss dose, finasteride cut PSA by about half in men aged 50 to 60 in a 48-week trial.6

What is a PSA test? Copy link

A PSA test is a blood test for prostate-specific antigen, reported in nanograms per milliliter (ng/mL). Doctors use it to look for prostate cancer early and to follow men already treated for it.4 Like most lab tests, it is read against an interval printed beside the result.

Normal and cancerous prostate cells both make PSA.4 Its everyday job is thinning semen, so nearly all of it stays in the prostate. A small amount reaches the blood, and most of that travels bound to other proteins. The unbound share is called free PSA.7 A report line that says "PSA" or "total PSA" counts both together.

The sample is ordinary blood, drawn from an arm vein.8 In many Indian cities a laboratory will collect it at your home. Private booking pages promise the report within about 6 to 24 hours.9

Why test at all? Prostate cancer is the third most common cancer in Indian men, after lung and mouth cancer. India's cancer registry estimated 43,691 new cases in 2022 and put the cumulative risk by age 74 at 1 in 125.10 Many are found late. Among 9,547 cases recorded by hospital-based cancer registries from 2012 to 2019, about 43 in 100 had already spread to distant parts of the body at diagnosis.11 Those registries count men treated at cancer hospitals, so the share across all Indian men may differ.

PSA levels by age Copy link

There is no single normal PSA, and the usual spread climbs as men age.4 In a 2023 study of 86,728 Indian men tested at health checkups, 95 in 100 were at or under 1.4 ng/mL up to age 40. That 95th-percentile value rose to 1.7 at 41 to 50, 3.1 at 51 to 60, 5.8 at 61 to 70 and 8.82 at 71 to 80.2 These are reference values from one study. They describe healthy-looking men and do not mark where cancer starts.

PSA test reference values by age: where 95 in 100 Indian men fell, beside the 1993 US chart Paired bars by decade show the PSA level that 95 in 100 healthy men stayed at or under. These are reference distributions, not cancer cut-offs and not safe upper limits. Indian men (86,728 men at health checkups, 2023; age groups 41 to 50, 51 to 60, 61 to 70, 71 to 80): 1.7, 3.1, 5.8 and 8.82 ng/mL. US chart (471 men, 1993; age groups 40 to 49 and so on): 2.5, 3.5, 4.5 and 6.5 ng/mL. PSA TEST · AGE-SPECIFIC VALUES PSA reference values by age REFERENCE DISTRIBUTION, NOT A CANCER CUT-OFF India, 86,728 men (2023), ages as labelled US chart, 471 men (1993), ages 40–49 and so on 41–50 1.7 2.5 51–60 3.1 3.5 61–70 5.8 4.5 71–80 8.82 6.5 Sources: Addla 2023 (India), Oesterling 1993 (US). 95 in 100 healthy men at or under, ng/mL. Below the value does not rule cancer out.
Figure 1. The PSA level that 95 in 100 healthy men stay at or under, by decade. Coral bars: 86,728 Indian men tested at health checkups, in age groups 41 to 50, 51 to 60 and so on. Gray bars: the 1993 US chart from 471 men, in age groups 40 to 49 and so on. Both are reference distributions from healthy men, not cancer cut-offs and not safe upper limits, and India's urology guideline has no age chart of its own. References 2, 12 and 1.

Is your number under the value for your age? That is not a safe upper limit. A man in his 70s at 8.0 ng/mL sits below 8.82, and his doctor may still want to look further, depending on his exam, earlier results and family history. The figures show where one group of men fell. They do not rule cancer out for you.2, 4

The chart printed on many reports comes from a different population. Its familiar steps, 2.5, 3.5, 4.5 and 6.5 ng/mL, were set in 1993 from 471 healthy men in Olmsted County, Minnesota.12 The UK's National Institute for Health and Care Excellence (NICE) uses the same four numbers. For NICE they are the levels at which a man with urinary symptoms is referred for cancer checks.13

PSA by age in healthy Indian men (2023) beside the 1993 US chart. Both columns are reference values from healthy men, not cancer cut-offs or official Indian ranges. The Indian age groups run 41 to 50, 51 to 60 and so on; the US groups run 40 to 49, 50 to 59 and so on. Values in ng/mL.
AgeIndian men: 95 in 100 at or underIndian men: middle value (median)1993 US chart: upper limit
Up to 401.400.60not set
40s1.700.602.5
50s3.100.743.5
60s5.800.994.5
70s8.821.306.5
Over 8011.311.70not set

Look at the pattern. Indian values sit below the American chart up to 60 and above it from the 60s on, by 1.3 ng/mL in the 60s and 2.3 in the 70s.2 The authors suggest some older men in their sample may have had a cancer nobody had found, which would lift the top of the range.2

Read the Indian figures with their limits in mind. The men came to health checkups at two hospitals in south India, though they lived across the country. Anyone with a PSA under 0.2 or over 20 was left out. The study did not track who later had a biopsy, so "healthy" means no known prostate disease at the checkup.2 Indian studies also disagree with each other. A community study in Gujarat put the upper limits at 2.1, 3.4, 4.2 and 5.0 ng/mL for men in their 40s, 50s, 60s and 70 and over.14 India's urology guideline has not adopted an age chart. It lists age-specific PSA values as something still to be worked out for Indian men.1

Many Indian lab pages list a single interval for every age, often under 4 ng/mL.9 So a 45-year-old at 3.0 sees no flag, though 95 in 100 Indian men his age in that study were lower. Where does yours sit? Treat both lines as context to discuss with your doctor, alongside your symptoms, family history and any medicines.

A low number carries real information too. The American Urological Association (AUA) guideline cites long-term data on men whose PSA was under 1 ng/mL at 60. Over the next 25 years, their risk was 0.5 percent for spread of prostate cancer and 0.2 percent for death from it.3

What does a high PSA mean? Copy link

A high PSA means more PSA is leaking into your blood than usual, and an enlarged prostate, an infection or a cancer can each cause that. Unsurprisingly, the higher the number, the more likely cancer becomes. No level proves it.4, 15

Indian men tend to reach a biopsy later and with higher numbers. India's urology guideline notes that Indian men are diagnosed at a higher PSA, above 10 ng/mL, than men in Western countries.1 In 2,479 men biopsied at 43 Indian centers in 2023 and 2024, the median PSA was 19.8 ng/mL.16

High PSA test results: cancer found among men already chosen for biopsy, by PSA level, 43 Indian centers Bar chart from an audit of 2,479 men biopsied at 43 Indian centers in 2023 and 2024, all already referred for biopsy. Cancer was found in 23.4% with PSA under 4, 39.5% at 4 to 10, 57.7% at 10 to 20, 68.4% at 20 to 50 and 83.3% above 100 ng/mL. The 50 to 100 band is left blank because the paper's table gives 68.4% and its text 75.5%. PSA TEST · 2,479 MEN ALREADY CHOSEN FOR BIOPSY Cancer found among men biopsied Men with cancer at biopsy, % 23.4% Under 4 39.5% 4–10 57.7% 10–20 68.4% 20–50 not shown* 50–100 83.3% Over 100 PSA before biopsy, ng/mL Source: Prasad et al., Indian J Urol 2026. *50–100 left blank: the paper's Table 4 gives 68.4%, its text 75.5%.
Figure 2. Cancer found at biopsy at each PSA level, among 2,479 men already chosen for biopsy at 43 Indian centers between June 2023 and June 2024. Most had urinary symptoms, so the percentages run far higher than the chance of cancer for a man having a routine PSA test. *The 50 to 100 band is left blank because the published paper is internally inconsistent there: its Table 4 reports 68.4 percent and its Results and Discussion text reports 75.5 percent. Reference 16.

In that audit, cancer turned up in 39.5 of every 100 men with a PSA of 4 to 10. The figure was 57.7 at 10 to 20 and 83.3 above 100. For 50 to 100 the paper gives two numbers, 68.4 in its table and 75.5 in its text.16 Keep in mind who these men were. About 70 in 100 had moderate or severe urinary symptoms, and all had been sent for biopsy.16 Even below 4, 23.4 in 100 of them had cancer, which shows how selected the group was.16 A man tested at a routine checkup starts from lower odds. In an audit from two Indian hospitals, PSA was raised in 28.4 in 100 men tested for urinary symptoms. Among healthy men at executive health checks, the figure was 3 in 100.17

PSA under 1 ng/mL

For most men not taking a medicine that lowers PSA, this is a low result. In the Indian data, the median sits between 0.6 and 1.0 ng/mL until 70.2 European guidance ties the gap to a baseline test. If your PSA was 1 or under at 40, or 2 or under at 60, the gap before the next test can stretch to eight years. Above those values, a test every two years may be offered. The gap your doctor suggests also depends on your risk and life expectancy.5

PSA 1 to 4 ng/mL

Most men in this band have no cancer, but a normal PSA lowers the odds without removing them. In one US trial, men aged 62 to 91 had a biopsy when the trial ended, whatever their PSA. Cancer was found in 15.2 percent of those with a PSA of 4 or less, and in 26.9 percent of those between 3.1 and 4.0.18 Most were low grade. About 15 in 100 of those cancers were a higher grade, Gleason 7 or above. The Gleason score grades how abnormal the cells look.18 Your doctor weighs your age, family history and any symptoms in deciding whether a 3.0 needs a repeat test.

PSA 4 to 10 ng/mL

Doctors often call this the borderline range, or gray zone. About 1 man in 4 in this range has prostate cancer, by American figures.15 The first step is usually a repeat test, after removing anything that can push PSA up.3, 5 In a US study of 972 men followed for four years, 44 percent of those with a PSA above 4 had a normal reading at a later visit.19 If the repeat stays raised, free PSA, PSA density and an MRI help decide about a biopsy. India's urology guideline reserves the derived measures, free PSA and density, for this 4 to 10 band.1

PSA 10 to 20 ng/mL, and does a PSA of 14 mean cancer?

A PSA of 14 does not mean cancer by itself. The odds, though, now lean toward it. American data put the chance of cancer above 50 percent once PSA passes 10.15 In the Indian biopsy audit the figure was 57.7 percent at 10 to 20.16 Infection, a recent catheter and a bladder that cannot empty can still raise PSA, so those are ruled out first.3 In practice, your doctor will usually repeat the test, ask about symptoms and arrange an MRI.3, 5

PSA above 20, and is there a dangerous PSA level?

No single number marks a cancer as dangerous. In 102,076 Swedish men already diagnosed with prostate cancer, 71 percent of those with a PSA above 100 had disease that had spread. Yet the researchers found no PSA cut-off that picked out most men with spread on its own.20 In the Indian audit, cancer was found in 68.4 percent of men biopsied at 20 to 50 and 83.3 percent above 100. At 50 to 100 the paper's table says 68.4 percent and its text says 75.5.16 With odds like these, an early urology review makes more sense than a long wait for a routine repeat.

What raises PSA besides cancer? Copy link

An enlarged prostate, a prostate or urine infection, and recent procedures on the bladder or prostate are the main non-cancer reasons for a raised PSA.21, 3 Ejaculation and long bike rides can nudge it up a little.

An enlarged prostate. As you would expect, a bigger gland leaks more PSA. In the 1993 Minnesota study, prostate size tracked PSA more closely than age did.12 This growth, called benign prostatic enlargement or BPH, is common and is not cancer.22

Infection or inflammation. A prostate infection, or a recent biopsy, can keep PSA high for a month or two.4 The NHS advises waiting 4 to 6 weeks after a urine infection has cleared before you test.21 Pain or burning when you pass urine before a test is worth reporting. A urine culture checks the sample for the germs behind a urinary infection.23

Tubes and procedures. A recent urinary catheter, a cystoscopy (a camera passed into the bladder) or a prostate biopsy can raise PSA for a while. So can a bladder that cannot empty.3 PSA itself has a half-life of about 2 to 3 days.3 Even so, after an infection or a biopsy the blood level can take weeks to return to its usual value.4

Ejaculation. The effect is small, and the studies disagree. In 100 men aged 25 to 35, PSA did not change 1 or 24 hours after ejaculation.24 In 62 men with urinary symptoms, it rose.25 The AUA guideline sums up controlled studies as showing no change or a rise of about 10 percent.3

Cycling. A review of eight studies with 912 men found no significant rise after cycling.26 One study did find a 9.5 percent average rise in 129 men aged 50 and over after rides of 55 to 160 km.27 Going by those two results, a short commute seems unlikely to matter. A long ride the day before your test might.

A rectal examination. A doctor's finger examination of the prostate made no clinically important difference to PSA in 2,754 men.28 The AUA guideline reaches the same view.3 Some Indian labs still ask you to wait up to 7 days after a rectal exam or prostate ultrasound before giving blood.9 Following the lab's rule costs you nothing.

Testosterone treatment. In 790 men aged 65 and over with low testosterone, a year of testosterone treatment raised PSA by an average of 0.47 ng/mL, against 0.06 on placebo. A confirmed PSA above 4.0 appeared in 1.9 percent on testosterone and 0.3 percent on placebo.29

Do finasteride and dutasteride lower PSA? Copy link

Yes, by about half. Finasteride and dutasteride are medicines for an enlarged prostate, and finasteride at a lower dose treats male-pattern hair loss.30, 31, 6 The drop builds over 3 to 6 months. If you take either one, your report shows a lower number than it would off the drug.

The prostate-dose labels are specific. Finasteride 5 mg cut PSA by about 50 percent within six months. The label tells doctors to double the PSA for comparison with men not taking the drug. It sets a new baseline at least six months after starting.30 Dutasteride also cut PSA by about 50 percent, within 3 to 6 months, and its label gives the same doubling rule after 3 months.31

PSA test on finasteride 1 mg for hair loss: median PSA change in a 48-week randomized trial Diverging bars from a trial of 355 men aged 40 to 60 with male-pattern hair loss. Median PSA fell 40% on finasteride 1 mg in men aged 40 to 49 (placebo 0%) and 50% in men aged 50 to 60 (placebo rose 13%). PSA TEST · RANDOMIZED TRIAL, 355 MEN Finasteride 1 mg and PSA Finasteride 1 mg a day Placebo Age 40–49 −40% 0% Age 50–60 −50% +13% Median change in PSA over 48 weeks Source: D'Amico and Roehrborn 2007, Lancet Oncology. Hair-loss dose, men aged 40 to 60.
Figure 3. Median change in PSA after 48 weeks in a randomized trial of 355 men aged 40 to 60 with male-pattern hair loss, taking finasteride 1 mg a day or a placebo. Reference 6.

The hair-loss dose does nearly the same. A randomized trial gave 355 men aged 40 to 60 either finasteride 1 mg a day or a placebo for 48 weeks. In men in their 40s, the median PSA fell by 40 percent, against no change on placebo. In men aged 50 to 60 it fell by 50 percent, while PSA on placebo rose by 13 percent. The authors concluded the adjustment used for 5 mg should apply to 1 mg as well.6 The fall looked smaller in younger men. In the hair-loss trials of men aged 18 to 41, the average PSA started at 0.7 ng/mL and stood at 0.5 a year later.32

Put that into numbers. Take a 55-year-old who has used finasteride for a year and reads 2.0 ng/mL. He would be compared with untreated men as if he read about 4.0. That takes him from well inside the usual spread for his age to above both the Indian 95th-percentile value of 3.1 and the US chart's 3.5.

Doubling is an estimate. The AUA guideline points out that responses vary. In one trial, only a third of men had a 40 to 60 percent fall at one year.3 The hair-loss label points to a more reliable signal. It asks for any confirmed rise from your lowest PSA on the drug to be checked, even while the number stays inside the normal range.32 Missed doses change the reading too.32 So tell the doctor reading your report that you take finasteride, at what dose, and since when. The 5 mg label adds that percent free PSA stays constant on the drug, so it needs no adjustment.30

A few common medicines and body size have smaller effects. In a US survey of 1,864 men, five years of regular use went with a lower PSA. The drop was 6 percent for anti-inflammatory painkillers, 13 percent for statins and 26 percent for thiazide water tablets.33 Statins are the cholesterol tablets prescribed after a high LDL on a lipid profile test. That survey measured an association at one time point, so it cannot show cause. Weight matters too. In 13,634 men treated for prostate cancer, PSA ran 11 to 21 percent lower in those with a body mass index of 35 or more. The likely reason is dilution, with the same PSA spread through more blood.34

Free PSA, PSA density and other add-on tests Copy link

Free PSA is the share of PSA that is not bound to blood proteins, reported as a percentage of total PSA. A low percentage points more toward cancer, and a high one toward benign enlargement.35

The test earns its place when total PSA is between 4 and 10. In a trial of 773 men aged 50 to 75 with a PSA in that range, the chance of cancer ran from 8 to 56 percent. The lower the free percentage, the higher the chance. Taking biopsies only below 25 percent free still found 95 percent of the cancers, and spared 20 percent of the unnecessary biopsies.35 US cancer guidance describes doctors advising a biopsy at 10 percent free or less, and suggesting men consider one between 10 and 25 percent.15

Repeat a free PSA at one lab where possible. In a 2021 comparison of three machines, total PSA results differed by about 1 to 5 percent. Free PSA differed by up to about 17 percent.36

PSA density

PSA density is your PSA divided by your prostate's volume in milliliters. The volume comes from an MRI or a transrectal ultrasound, where the probe sits in the back passage. Take two men who both read 6 ng/mL. With a 60 mL prostate the density is 0.10. With a 30 mL prostate it is 0.20, which is more suspicious. The AUA guideline notes that with a density under 0.15, some men with a normal MRI can avoid a biopsy.3 European guidance uses under 0.20, together with a normal MRI and no family history.5 In a community study in Gujarat, 95 in 100 men had a density at or under 0.19.14

PSA velocity

Velocity is how fast PSA rises from year to year. Adding it to a single PSA reading barely improved accuracy in 5,519 men, and the researchers found no support for biopsy on high velocity alone.37 The AUA guideline says velocity should not be the sole reason for further tests.3

Prostate Health Index

The Prostate Health Index, or PHI, combines total PSA, free PSA and a PSA fragment called p2PSA into one score. In one lab's published bands for men 50 or older with a total PSA of 4 to 10, the chance of cancer ran from 9.8 percent for the lowest scores to 50.1 percent for the highest.38 Its job is to help decide whether a biopsy is needed.4 At least one Indian lab chain lists it, at about ₹2,960.9

What happens after a high PSA? Copy link

Doctors usually confirm a new rise first and weigh your overall risk before deciding whether an extra marker test, an MRI or a biopsy comes next. The AUA asks for a newly raised PSA to be repeated before any scan or biopsy.3 European guidance asks for the same in men without symptoms whose PSA is 3 to 10. It then lists an MRI as one of three tools for deciding on a biopsy, alongside a risk calculator and an extra blood or urine marker.5 Ask which of them your doctor plans to use.

  1. Repeat the test a few weeks later at the same lab, with no infection, catheter, long ride or recent ejaculation in the way.19, 21
  2. Add free PSA or density if the repeat sits between 4 and 10.1
  3. An MRI, if your doctor wants to look further. That call rests on the repeat PSA, the exam, your family history and overall risk. Once a biopsy is on the table, European guidance recommends an MRI before it. The radiologist scores any suspicious area from 1 to 5, a scale called PI-RADS.5
  4. Biopsy only if needed. With a normal MRI, low density and no family history, European guidance supports PSA monitoring without a biopsy, as a weak recommendation.5

The MRI step changes what gets found. In a trial of men with a suspected cancer, an MRI-directed biopsy found clinically significant cancer in 38 percent, against 26 percent with the older standard biopsy. Clinically significant means the kind likely to need treatment. It also found fewer cancers unlikely to cause harm.39 In a Swedish screening trial, testing with PSA plus MRI halved diagnoses of cancers unlikely to cause harm, from 1.2 to 0.6 percent.40

Practice in India is mixed. In the 43-center audit, 45.6 in 100 men had an MRI before their biopsy. Cancer was found in 81.4 percent of men whose MRI scored 5, and in 23.1 percent of those scoring 2.16 Biopsy is not trivial. In the same audit, 11.1 in 100 men had a complication. The commonest was blood in the urine for more than a day, and 5 in 1,000 were admitted with sepsis, a serious blood infection.16 Is an MRI part of your plan? You can ask whether one comes first.

Should you get a PSA test, and from what age? Copy link

A PSA test is a choice you make with your doctor. India's national framework for common cancers, published in 2016, covers screening for oral, breast and cervical cancer only.41 India's urology guideline suggests deciding case by case after 50, for men expected to live another 10 to 15 years or more. For men at higher risk, it pairs PSA with a rectal exam.1

Other guidelines draw the lines a little differently.

  • United States, American Urological Association (amended 2026): a first PSA between 45 and 50, then every 2 to 4 years from 50 to 69. Men at higher risk start at 40 to 45. That includes Black ancestry, an inherited gene change or a strong family history.3
  • Europe, European Association of Urology (2026): from 50; from 45 for men of African descent or with a relative diagnosed before 60; from 40 for carriers of a BRCA2 gene change. BRCA2 is an inherited fault also linked to breast cancer. A test every 2 years may be offered if PSA was above 1 at 40 or above 2 at 60, and the gap can stretch to 8 years if it was lower.5
  • United States, Preventive Services Task Force or USPSTF (2018, update under way): an individual decision at 55 to 69, and no routine screening from 70.42
  • United Kingdom, national screening committee (2026): PSA every 2 years from 45 to 61, only for men with a BRCA2 change and a family history of certain cancers.43 England's programme is expected to start in 2027.44

What does screening buy? A European trial followed 162,236 men aged 55 to 69 for a median of 23 years. Deaths from prostate cancer were 13 percent lower in the screened group.45

PSA test screening after 23 years: one prostate cancer death prevented per 456 men invited A grid of 456 squares with one highlighted, for the European screening trial of 162,236 men aged 55 to 69 followed for 23 years. One prostate cancer death was prevented for every 456 men invited and for every 12 extra men diagnosed. Deaths from prostate cancer were 13% lower with screening. PSA SCREENING · EUROPEAN TRIAL, 162,236 MEN PSA screening over 23 years 456 men invited per death prevented 12 extra diagnoses per death prevented 13% fewer prostate cancer deaths Source: Roobol 2025, ERSPC, New England Journal of Medicine. Median follow-up 23 years.
Figure 4. Each square stands for one man invited to PSA screening in a European trial of 162,236 men aged 55 to 69. Over a median of 23 years, one prostate cancer death was prevented for every 456 men invited and for every 12 extra men diagnosed, and deaths from prostate cancer were 13 percent lower with screening. A schematic count, not individual patients. Reference 45.

In absolute terms, one death was prevented for every 456 men invited to screening, and for every 12 extra men diagnosed. Screening also raised the number of cancers found by 30 percent.45 Some of those cancers would never have caused harm. The USPSTF estimates that 20 to 50 percent of men diagnosed through screening may be overdiagnosed. Their cancer would never have caused symptoms in their lifetime.42

Family genes shift the balance. A 2026 study screened 3,063 men aged 40 to 69 every year, comparing carriers of BRCA gene changes with non-carriers. Over five years, clinically significant cancer turned up in 3.1 percent of BRCA2 carriers and 1.3 percent of non-carriers.46 If your father or brother had prostate cancer, or a relative carries a BRCA change, say so before deciding when to start.

Are you booking a preventive health package? Check whether PSA appears by name in its test list, since packages vary.

How to prepare for a PSA test Copy link

Fasting is not required before a PSA test. The NHS says you can eat and drink as usual.21 What matters more is the 48 hours before the blood draw. Run through this list first.

  • No ejaculation for 24 to 48 hours beforehand; MedlinePlus says 24, the NHS says 488, 21
  • No cycling, and no exercise that leaves you breathless, for 48 hours21
  • A wait of 4 to 6 weeks after a urine infection clears21
  • A word with your doctor about timing after a biopsy, catheter or cystoscopy, since a biopsy can keep PSA raised for a month or two4
  • The names of any finasteride, dutasteride or testosterone you take, written on the lab form
  • The same lab each time, so the machine stays the same36

PSA test price in India Copy link

A total PSA test costs ₹404 to ₹475 at CGHS Tier I rates, the price list of the health scheme for central government staff, and private booking pages list about ₹350 to ₹1,200.47, 9

CGHS pays ₹475 at accredited laboratories and ₹404 at others. A free PSA is ₹800 and ₹680. For Tier II cities, take off 10 percent; for Tier III, 20 percent.47 One government teaching hospital, AIIMS Mangalagiri, charges ₹275 each for total and free PSA.48

On private booking pages checked on 6 October 2026, most national chains priced a total PSA between ₹650 and ₹1,000. A free PSA ran from about ₹400 to ₹990.9 Crossed-out "MRP" figures of ₹1,500 to ₹2,800 were list prices, well above what the same pages charged. At CGHS Tier I accredited rates, a total and a free PSA billed separately add up to ₹1,275.

PSA after prostate cancer treatment Copy link

After surgery to remove the prostate, PSA should fall to a very low or undetectable level within a couple of months. Doctors usually wait at least 6 to 8 weeks before the first check.49 A PSA of 0.2 ng/mL or more on two separate tests is what doctors call biochemical recurrence. It means the cancer may be active again and needs a specialist's review. By itself it does not show where the cancer is, or whether treatment must start at once.50

After radiotherapy, PSA falls slowly and may take 2 years or more to reach its lowest point. A rise of 2 ng/mL above that lowest point is the standard definition of biochemical recurrence after radiotherapy.49, 50 India's urology guideline uses the same rise.1

When a PSA result needs a doctor soon Copy link

A newly raised PSA usually gets a repeat test first, and a high number by itself is no reason to go to an emergency department.3 Two situations are emergencies.

  • You cannot pass urine, or you have severe pain in your belly. US kidney-health guidance says to see a health professional right away.51
  • Sudden back pain with weak legs, numbness around the groin or bottom, or new trouble controlling your bladder or bowel. In prostate cancer these can mean pressure on the spinal cord, which needs emergency care.52

Three others call for a doctor within days, not months.

  • A repeat test confirms a PSA above 20 ng/mL, the range where most men biopsied in India had cancer. Ask for a urologist.16
  • A raised PSA comes with blood in your urine or semen, new back pain, or weight loss you cannot explain.22
  • A repeat test confirms a rise from your lowest PSA while you take finasteride. The doctor who prescribes it should see the result.32, 30

For everything else, bring your result to the appointment along with your age, symptoms and medicines. In the Indian study, 95 in 100 men were at or under 1.7 ng/mL in their 40s and 5.8 in their 60s, figures to discuss with your doctor. On finasteride, doubling the reading gives a rough figure to compare.2, 30

Frequently asked questions Copy link

Can women have a PSA test?

Women make tiny amounts of PSA. A very sensitive test found it in about 75 in 100 blood samples from women with a benign breast condition. The reference ranges, cut-offs and screening advice on this page are written for men. A PSA result in a woman needs a doctor to explain why it was ordered.53

Which warning signs can prostate cancer cause?

Early prostate cancer often causes no symptoms. Later signs include straining or a weak stream, passing urine often or at night, blood in urine or semen, and erection problems. Back pain and unexplained weight loss can mean spread. The same urinary symptoms can also come from an enlarged prostate, which is not cancer.22

Can a PSA test be done at home, and how soon is the report ready?

In many Indian cities a lab technician can draw the blood at your home and take it to the laboratory, where the test runs. Private booking pages advertise reports within about 6 to 24 hours. Ask for the result in ng/mL, with the lab's reference interval printed beside it.9

Can a high PSA go back to normal?

Often, yes. A newly raised PSA returns to normal on retesting in 25 to 40 in 100 men. An infection or inflammation can keep PSA raised for several weeks. PSA itself has a half-life of about 2 to 3 days, but the blood level may take much longer to return to its usual value. Doctors confirm a raised result before any scan or biopsy.3, 4

References Copy link

  1. Kumar A, Yadav S, Krishnappa RS, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary). Indian J Urol. 2022;38(4):252-257. A correction was published in Indian J Urol. 2022;39(1):86. doi:10.4103/iju.iju_232_22
  2. Addla SK, Selvaraj N, Sakthivel DK, Ragavan N. Determining age-specific prostate-specific antigen for healthy Indian men: A retrospective study. Indian J Urol. 2023;39(4):317-321. doi:10.4103/iju.iju_244_23
  3. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026). American Urological Association; amendment published 26 February 2026. auanet.org (PDF)
  4. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Updated 31 January 2025. cancer.gov
  5. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel. EAU Guidelines on Prostate Cancer, 2026 edition. Chapter: Diagnostic evaluation. European Association of Urology; 2026. uroweb.org
  6. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8(1):21-25. doi:10.1016/S1470-2045(06)70981-0
  7. David MK, Leslie SW. Prostate-Specific Antigen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 10 September 2024. ncbi.nlm.nih.gov
  8. MedlinePlus, National Library of Medicine. Prostate-Specific Antigen (PSA) Test. Updated 19 May 2025. medlineplus.gov
  9. Published prices, home-collection terms and report times for PSA tests, taken from the public booking pages of eleven private diagnostic providers and one price aggregator in India on 6 October 2026. Individual provider pages are held in the Sapiens editorial ledger and are not reproduced here. Prices change. editorial standards
  10. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022;156(4&5):598-607. doi:10.4103/ijmr.ijmr_1821_22
  11. Sankarapillai J, Krishnan S, Ramamoorthy T, Sudarshan KL, Mathur P. Descriptive epidemiology of prostate cancer in India, 2012–2019: Insights from the National Cancer Registry Programme. Indian J Urol. July 2024. doi:10.4103/iju.iju_27_24
  12. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum Prostate-Specific Antigen in a Community-Based Population of Healthy Men: Establishment of Age-Specific Reference Ranges. JAMA. 1993;270(7):860-864. doi:10.1001/jama.1993.03510070082041
  13. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Recommendation 1.6.3 and table 2 [2021]. Guideline last updated 15 April 2026. nice.org.uk
  14. Ganpule AP, Desai MR, Manohar T, Bapat S. Age-specific prostate specific antigen and prostate specific antigen density values in a community-based Indian population. Indian J Urol. 2007;23(2):122-125. doi:10.4103/0970-1591.32060
  15. American Cancer Society. Screening Tests for Prostate Cancer. Last revised 22 November 2023. cancer.org
  16. Prasad V, Agrawal S, Pooleri GK; USI CRC Group. Evaluating prostate biopsy practices across Indian institutions: A multi-center prospective observational study. Indian J Urol. 2026;42(1):51-66. Published online 2 December 2025. doi:10.4103/iju.iju_212_25
  17. Mandhani A, Mittal V, Bhaskar V, Srivastava A. Prostate-specific antigen screening of men with lower urinary tract symptoms (opportunistic screening) and of asymptomatic men undergoing executive health check: an audit from two institutions. Indian J Urol. 2021;37(2):159-162. doi:10.4103/IJU.IJU_478_20
  18. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med. 2004;350(22):2239-2246. doi:10.1056/NEJMoa031918
  19. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695-2700. doi:10.1001/jama.289.20.2695
  20. Thomsen FB, Westerberg M, Garmo H, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS One. 2020;15:e0228447. doi:10.1371/journal.pone.0228447
  21. NHS. PSA test. Page last reviewed 2 September 2024. nhs.uk
  22. NHS. Symptoms of prostate cancer. Page last reviewed 31 July 2025. nhs.uk
  23. MedlinePlus Medical Encyclopedia. Urine culture. Review date 9 October 2024. medlineplus.gov
  24. Heidenreich A, Vorreuther R, Neubauer S, et al. The influence of ejaculation on serum levels of prostate specific antigen. J Urol. 1997;157(1):209-211. scholars.duke.edu (abstract)
  25. Tarhan F, Demir K, Orçun A, Madenci OC. Effect of ejaculation on Serum Prostate-Specific Antigen concentration. Int Braz J Urol. 2016;42(3):472-478. doi:10.1590/S1677-5538.IBJU.2015.0116
  26. Jiandani D, Randhawa A, Brown RE, et al. The effect of bicycling on PSA levels: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015;18:208-212. doi:10.1038/pcan.2015.16
  27. Mejak SL, Bayliss J, Hanks SD. Long Distance Bicycle Riding Causes Prostate-Specific Antigen to Increase in Men Aged 50 Years and Over. PLoS One. 2013;8:e56030. doi:10.1371/journal.pone.0056030
  28. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267(16):2227-2228. scholarlyworks.lvhn.org (abstract)
  29. Cunningham GR, Ellenberg SS, Bhasin S, et al. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab. 2019;104(12):6238-6246. doi:10.1210/jc.2019-00806
  30. US Food and Drug Administration. PROSCAR (finasteride) tablets, for oral use: prescribing information, section on effects on prostate specific antigen. Revised 3/2026. accessdata.fda.gov (PDF)
  31. US Food and Drug Administration. AVODART (dutasteride) soft gelatin capsules: prescribing information, section on effects on prostate-specific antigen. Revised 1/2020. accessdata.fda.gov (PDF)
  32. US Food and Drug Administration. PROPECIA (finasteride) tablets, for oral use: prescribing information, section 5.2. Revised 7/2022. accessdata.fda.gov (PDF)
  33. Chang SL, Harshman LC, Presti JC Jr. Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010;28(25):3951-3957. doi:10.1200/JCO.2009.27.9406
  34. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. JAMA. 2007;298(19):2275-2280. doi:10.1001/jama.298.19.2275
  35. Catalona WJ, Partin AW, Slawin KM, et al. Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial. JAMA. 1998;279(19):1542-1547. doi:10.1001/jama.279.19.1542
  36. Garrido MM, Marta JC, Ribeiro RM, et al. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations. In Vivo. 2021;35(6):3431-3439. doi:10.21873/invivo.12643
  37. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. J Natl Cancer Inst. 2011;103(6):462-469. doi:10.1093/jnci/djr028
  38. Mayo Clinic Laboratories. Prostate Health Index Reflex, Serum (test ID PHI11). Test catalog. mayocliniclabs.com
  39. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19). doi:10.1056/NEJMoa1801993
  40. Hugosson J, Månsson M, Wallström J, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med. 2022;387:2126-2137. doi:10.1056/NEJMoa2209454
  41. Ministry of Health and Family Welfare, Government of India. Operational Framework: Management of Common Cancers. 2016. nhsrcindia.org (PDF)
  42. US Preventive Services Task Force. Prostate Cancer: Screening. Final recommendation statement, 8 May 2018. The page states the topic is being updated. uspreventiveservicestaskforce.org
  43. UK National Screening Committee. Minutes published of UK NSC March 2026 meeting. 28 May 2026. nationalscreening.blog.gov.uk
  44. Department of Health and Social Care, UK Government. Major expansion of research and treatment for prostate cancer. Press release, 2 June 2026 (updated 10 September 2026). gov.uk
  45. Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening - 23-Year Follow-up. N Engl J Med. 2025;393(17):1669-1680. doi:10.1056/NEJMoa2503223
  46. Bancroft EK, Page EC, et al; IMPACT Study Collaborators. Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study. Eur Urol. 2026;89:457-468. doi:10.1016/j.eururo.2026.01.031
  47. Ministry of Health and Family Welfare, Central Government Health Scheme. Office Memorandum F.No.5-16/CGHS(HQ)/HEC/2024(PartI): CGHS rates applicable for treatment at healthcare organisation. 3 October 2025; rates effective 13 October 2025. Codes LB142, LB143. s3waas.gov.in (PDF)
  48. All India Institute of Medical Sciences, Mangalagiri. Hospital user charges (PDF, uploaded January 2026). Accessed 6 October 2026. aiimsmangalagiri.edu.in (PDF)
  49. American Cancer Society. Following PSA Levels During and After Prostate Cancer Treatment. Last revised 11 September 2026. cancer.org
  50. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509-517. auanet.org
  51. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of Urinary Retention. Last reviewed December 2019. niddk.nih.gov
  52. Cancer Research UK. Spinal cord compression. Last reviewed 24 January 2024. cancerresearchuk.org
  53. Borchert GH, Yu H, Tomlinson G, et al. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. J Clin Lab Anal. 1999;13(2). pmc.ncbi.nlm.nih.gov

This article is general health information for readers in India and does not diagnose anything. A PSA result is read together with your age, symptoms, examination and any medicines you take, so discuss your report with your doctor. Prices are the published rates and list prices named in the references, checked on 6 October 2026, and they change. Sapiens is operated by Pangaea Sciences Private Limited, Hyderabad. Report an error on this page.

Written by Dr. Tarun Reddy, MBBS · Registered medical practitioner (TSMC/FMR/36195) at Sapiens · Published 20 October 2026 · Editorial standards